[go: up one dir, main page]

AU2001225164A1 - Compositions with enhanced oral bioavailability - Google Patents

Compositions with enhanced oral bioavailability

Info

Publication number
AU2001225164A1
AU2001225164A1 AU2001225164A AU2516401A AU2001225164A1 AU 2001225164 A1 AU2001225164 A1 AU 2001225164A1 AU 2001225164 A AU2001225164 A AU 2001225164A AU 2516401 A AU2516401 A AU 2516401A AU 2001225164 A1 AU2001225164 A1 AU 2001225164A1
Authority
AU
Australia
Prior art keywords
compositions
oral bioavailability
enhanced oral
enhanced
bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001225164A
Inventor
Begona Carreno-Gomez
Ruth Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand International SpA filed Critical Eurand International SpA
Publication of AU2001225164A1 publication Critical patent/AU2001225164A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001225164A 2000-01-18 2001-01-16 Compositions with enhanced oral bioavailability Abandoned AU2001225164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00100886 2000-01-18
EP00100886A EP1118333A1 (en) 2000-01-18 2000-01-18 Compositions with enhanced oral bioavailability
PCT/EP2001/000415 WO2001052896A2 (en) 2000-01-18 2001-01-16 Compositions with enhanced oral bioavailability

Publications (1)

Publication Number Publication Date
AU2001225164A1 true AU2001225164A1 (en) 2001-07-31

Family

ID=8167646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001225164A Abandoned AU2001225164A1 (en) 2000-01-18 2001-01-16 Compositions with enhanced oral bioavailability

Country Status (5)

Country Link
US (1) US20030211072A1 (en)
EP (2) EP1118333A1 (en)
AU (1) AU2001225164A1 (en)
CA (1) CA2397781A1 (en)
WO (1) WO2001052896A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1315777B1 (en) 2000-09-06 2007-10-31 AP Pharma, Inc. Degradable polyacetal polymers
JP2005507933A (en) * 2001-10-29 2005-03-24 ザ ダウ ケミカル カンパニー Antineoplastic dendritic polymer drug delivery system
EP1696974B1 (en) * 2003-12-19 2007-05-23 Basf Aktiengesellschaft Swellable hydrogel-forming polymers having a low fine dust concentration
KR20050104152A (en) 2004-04-28 2005-11-02 최승호 Enhancing systems for poorly absorptive drugs
WO2006110656A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20080020043A1 (en) * 2006-07-20 2008-01-24 Marc Gingras Dendrimer-Drug Conjugates
US20080227892A1 (en) * 2007-03-13 2008-09-18 Van Der Wielen Maarten Paint formulations comprising cellulose ether/network building polymer fluid gel thickeners
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
ES2572631T3 (en) 2008-01-25 2016-06-01 Chimerix, Inc. Methods of treating viral infections
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
PL2534150T3 (en) 2010-02-12 2017-09-29 Chimerix, Inc. Methods of treating viral infection
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2883931A1 (en) * 2013-12-12 2015-06-17 Omya International AG Improved gel stability
US10420731B1 (en) 2019-01-18 2019-09-24 King Saud University Method of synthesizing lignin-based nanocompositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
IL128774A (en) * 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
SK282427B6 (en) * 1997-06-11 2002-01-07 Abbott Laboratories Solid pharmaceutical composition with controlled release
ATE321882T1 (en) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR ADMINISTRATION OF OLIGONUCLEOTIDES VIA THE ESOPHAUS
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
WO1999022739A1 (en) * 1997-10-31 1999-05-14 Taisho Pharmaceutical Co., Ltd. Medicinal steroid compound composition
AU1809499A (en) * 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
ATE327735T1 (en) * 1998-04-01 2006-06-15 Jagotec Ag TAXAN MICROEMULSIONS

Also Published As

Publication number Publication date
EP1261375A2 (en) 2002-12-04
WO2001052896A2 (en) 2001-07-26
WO2001052896A3 (en) 2002-03-07
US20030211072A1 (en) 2003-11-13
CA2397781A1 (en) 2001-07-26
EP1118333A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001259693A1 (en) Oral devices
AUPQ875700A0 (en) Combination compositions
AU4428000A (en) Pulse-delivery oral compositions
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU2001225164A1 (en) Compositions with enhanced oral bioavailability
AU2001267878A1 (en) Hypoglycemics
AU2001296622A1 (en) Oral devices
AU2001273919A1 (en) Pharmaceutical compositions
AU2001241098A1 (en) Composition
AU2002210433A1 (en) Dental compositions
AU2001270235A1 (en) Oral compositions
AU4085201A (en) Pharmaceutical composition
AU2001275201A1 (en) Acne-treating composition
AU2001290669A1 (en) Oral compositions
AU2001235764A1 (en) Compositions
AU2001287852A1 (en) Composition
AU2001223721A1 (en) Dental compositions
AU2001278788A1 (en) Oral composition
AU3586401A (en) Pharmaceutical composition
AU2001287732A1 (en) Copolycarbonate-based composition
AU2001278487A1 (en) Oral composition